Rocuronio-sugammadex para el manejo de la terapia electroconvulsiva en el síndrome neuroléptico maligno, a propósito de un caso

Casas Reza, P; Gestal Vázquez, M; Outeiro Rosato, A; López Álvarez, S; Diéguez García, P.
Rev. esp. anestesiol. reanim ; 64(2): 105-107, feb. 2017.
Artigo em Espanhol | IBECS | ID: ibc-159440

Documentos relacionados

  1. The neuroleptic malignant syndrome-a systematic case series analysis focusing on therapy regimes and outcome.
  2. Neuromuscular Blockers and Electroconvulsive Therapy: How Much Is Enough?
  3. BET 2: Is the use of long-acting neuromuscular blocking agents for intubation associated with reduced provision of postintubation sedation?
  4. Pharmacotherapy optimization for rapid sequence intubation in the emergency department.
  5. Nursing Considerations When Using Neuromuscular Blocking Agents to Assist With Intubation: A Review of Literature.
  6. The Nonirritating Concentrations of Neuromuscular Blocking Agents and Related Compounds.
  7. Expanding the Catatonia Tent: Recognizing Electroconvulsive Therapy Responsive Syndromes.
  8. Neuroleptic malignant syndrome: A case report.
  9. The decision to use succinylcholine for critically ill patients should not be based on duration of time in the intensive care unit alone.
  10. In response.